Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	685.02B -21.3%
Revenue (ttm)	247.29B +8.2%
Net Income	16.59B -2.1%
EPS	2,371.00 -0.3%
Shares Out	6.56M
PE Ratio	44.07
Forward PE	27.21
Dividend	1,200.00 (1.18%)
Ex-Dividend Date	Sep 29, 2025

Volume	37,709
Average Volume	43,251
Open	102,900
Previous Close	104,500
Day's Range	101,300 - 103,500
52-Week Range	96,400 - 182,700
Beta	0.49
RSI	41.12
Earnings Date	May 15, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 718
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 16.59 billion, a decrease of -2.13%.